Evaluate the efficacy of weekly adalimumab (ADA) in patients with non-infectious ocular inflammation who failed standard every other week (EOW) dosing.
Single-center, retrospective, study.
Patients with uncontrolled inflammation on ADA EOW who were escalated to weekly dosing.
Chart review conducted at Northwestern University, January 2012 to April 2019.
Outcome: Number of treatment successes on weekly ADA at 6 and 12 months.
Fourteen of 25 patients (56%) achieved disease control at 6 months; no additional failures occurred at 12 months.
Weekly ADA is a reasonable treatment option in patients with recalcitrant inflammation on standard dosing.